Securing Access and Reimbursement for Rare Disease Therapies

This report explores how payer approaches to access and reimbursement for rare disease therapies are changing in response to rising costs, increasing therapeutic options, and ongoing evidence limitations.

Drawing on payer survey findings and market experience, it highlights five key trends shaping rare disease management:

1. Expanded use case management programs
2. Greater reliance on external clinical experts
3. Growing adoption of value‑based and alternative payment models
4. Restriction of prescribing and administration to Centers of Excellence
5. More complex management when multiple therapies are available within the same indication

You'll also get practical recommendations that emphasize early payer engagement, strong evidence generation, use of real‑world data and registries, alignment with clinical experts and care centers, and sustained collaboration with payers.

What you'll learn:

Five payer trends influencing access for rare disease therapies
How payers are applying utilization management strategies as rare disease pipelines expand
What evidence, data sources, and partnerships payers value most when evaluating rare disease treatments
Actionable recommendations for manufacturers

Explore more resources

What We Heard at World EPA Congress 2026 & Why It Matters for Access Strategy

Securing Access and Reimbursement for Rare Disease Therapies

What you'll learn:

Fill out the form to access the report

Explore more resources

What We Heard at World EPA Congress 2026 & Why It Matters for Access Strategy

4 Key Pillars for Oncology Launch Success

What Physicians See When They Search Your Drug and Why It Probably Isn't What You Think